TIDMDPH
RNS Number : 5785E
Dechra Pharmaceuticals PLC
12 February 2018
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED
STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH
AFRICA, HONG KONG, SINGAPORE OR JAPAN OR ANY OTHER JURISDICTION IN
WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
PLEASE SEE THE IMPORTANT NOTICES WITHIN THIS ANNOUNCEMENT.
12 February 2018
Dechra Pharmaceuticals PLC (Dechra)
Results of General Meeting
Dechra is pleased to announce that at the General Meeting of
Dechra held earlier today, the Resolutions put to Dechra
Shareholders to, inter alia, approve the proposed Acquisition of
AST Farma B.V. (AST Farma) and Le Vet Beheer B.V. (Le Vet) was
passed with the requisite majority on a show of hands.
Full details of the Resolutions passed, together with the
explanatory notes, are set out in Dechra's circular to shareholders
dated 25 January 2018 (the "Circular"), including the Notice of
General Meeting, which is available on Dechra's website,
www.dechra.com. Capitalised terms used but not defined in this
announcement have the meaning given in the Circular.
The table below shows the proxy votes received for and against
the Resolutions.
Issued share capital at the date of the General Meeting:
98,617,327 ordinary shares
Details of the proxy voting instructions lodged prior to the
General Meeting are set out below:
Resolution Total For (1) Total Against Withheld
(No. as noted (2)
on proxy form)
------------------ ------------------- ---------------------- ----------
No. of % of No. of % of vote No. of
Votes vote Votes Votes
------------------ ----------- ------ ---------- ---------- ----------
Resolution
1:
To approve
the Acquisition 77,906,632 99.14 679,702 0.86 1,504,845
------------------ ----------- ------ ---------- ---------- ----------
Resolution
2:
To authorise
the Directors
to allot shares
to specific
limits 76,626,702 97.45 2,004,306 2.55 1,460,171
------------------ ----------- ------ ---------- ---------- ----------
Resolution
3:
To disapply
the pre-emption
rights 76,573,353 97.69 1,812,323 2.31 1,705,503
------------------ ----------- ------ ---------- ---------- ----------
Resolution
4:
To disapply
additional
pre-emption
rights 76,076,294 96.75 2,552,909 3.25 1,461,975
------------------ ----------- ------ ---------- ---------- ----------
Notes
1. Includes discretionary votes.
2. A "vote withheld" is not a vote in law and is not counted in
the calculation of the proportion of votes "For" and "Against" a
resolution.
3. Resolutions 1 to 2 were ordinary resolutions, requiring more
than 50% of shareholder votes to be "for" the resolutions.
4. Resolution 3 to 4 were special resolutions, requiring more
than 75% of shareholder votes to be "for" the resolutions.
5. Votes tendered in respect of 80,091,179 shares representing
81.21% of the issued share capital.
A copy of the Resolutions will be submitted to the National
Storage Mechanism in accordance with rule 9.6.2 of the UK Listing
Rules and will be available for inspection at
http://www.morningstar.co.uk/uk/NSM.
Completion of the Acquisition remains subject to satisfaction of
the outstanding conditions to Completion, summarised in the
Circular, which is expected on 13 February 2018. Admission of the
Consideration Shares is expected on the 14 February 2018.
For further information contact:
--------------------------------------- --------------------
Dechra Pharmaceuticals PLC Tel: +44 (0) 1606
814 730
Melanie Hall, Company Secretary
e-mail: corporate.enquiries@dechra.com
Investec Bank plc (Sole Sponsor, Tel: +44 (0) 20
Bookrunner and Broker) 7597 5970
Chris Treneman / Daniel Adams
/ Jonathan Wynn / Neil Coleman
TooleyStreet Communications Limited Office: +44 (0)
121 309 0099
Fiona Tooley, Director Mobile: +44 (0)
7785 703 523
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Its expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. The majority of its
products are focused on key therapeutic categories where it has
leading market positions, and many of its products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra 'D' logo are registered Trademarks of
Dechra Pharmaceuticals PLC.
IMPORTANT NOTICES
This announcement is for information purposes only and is not
intended to and does not constitute, or form part of, any offer or
invitation to purchase, subscribe for or otherwise acquire or
dispose of, or any solicitation to purchase or subscribe for or
otherwise acquire or dispose of, any securities in any
jurisdiction. Persons needing advice should consult an independent
financial adviser. The information contained in this announcement
is not for release, publication or distribution to persons in any
jurisdiction where to do so might constitute a violation of local
securities laws or regulations.
The information contained in this announcement is for background
purposes only and does not purport to be full or complete. The
information in this announcement is subject to change without
notice.
Investec Bank plc ("Investec") is authorised by the Prudential
Regulatory Authority and regulated in the United Kingdom by the
Prudential Regulation Authority and the Financial Conduct Authority
and is acting exclusively for Dechra and no one else in connection
with the Acquisition, the content of this announcement and other
matters described in this announcement. Investec will not regard
any other person as their client in relation to the Acquisition,
the content of this announcement and other matters described in
this announcement and will not be responsible to anyone other than
Dechra for providing the protections afforded to their respective
clients or for providing advice to any other person in relation to
the Acquisition, the content of this announcement or any other
matters referred to in this announcement.
This announcement has been issued by and is the sole
responsibility of Dechra. No representation or warranty, express or
implied, is or will be made as to, or in relation to, and no
responsibility or liability is or will be accepted by Investec or
by any of its affiliates or agents as to, or in relation to, the
contents of this announcement, including its accuracy, completeness
or verification or for any other statement made or purported to be
made by it, or on behalf of it, Dechra or any other person in
connection with Dechra, the Acquisition or for any other written or
oral information made available to or publicly available to any
interested party or its advisers, and nothing in this announcement
should be read as a promise or representation in this respect,
whether or not to the past or the future. Each of Investec and its
affiliates and agents disclaims to the fullest extent permitted by
law all and any responsibility or liability whatsoever, whether
arising in tort, contract or otherwise, which it might otherwise
have in respect of this announcement or any such statement.
Neither the content of Dechra's website (or any other website)
nor the content of any website accessible from hyperlinks on
Dechra's website (or any other website) is incorporated into or
forms part of this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMTTMLTMBIBMPP
(END) Dow Jones Newswires
February 12, 2018 04:51 ET (09:51 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024